330785-83-6

Basic information

• Product Name: 5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester
• Synonyms: 5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester;(S)-4-(3-chloro-4-MethoxybenzylaMino)-5-ethoxycarbonyl-2-(2-hydroxyMethyl-1-pyrrolidinyl)pyriMidine;4-[[(3-Chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-5-pyrimidinecarboxylic acid ethyl ester;(S)-ethyl 4-((3-chloro-4-Methoxybenzyl)aMino)-2-(2-(hydroxyMethyl)pyrrolidin-1-yl)pyriMidine-5-carboxylate;ethyl (S)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidine-5-carboxylate;5-Pyrimidinecarboxylic acid, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-, ethyl;(S)-Ethyl 4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidine-5;Ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-2-[(2S)-2-(hydroxymethy l)-1-pyrrolidinyl]-5-pyrimidinecarboxylate
• CAS NO: 330785-83-6
• Molecular Formula: C20H25ClN4O4
• Molecular Weight: 420.8899
• EINECS: -0
• Mol File: 330785-83-6.mol

Chemical Properties

• Boiling Point: 607.5±65.0 °C(Predicted)
• Appearance: /
• Density: 1.317±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: 5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester(330785-83-6)
• EPA Substance Registry System: 5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester(330785-83-6)

Safety Data

• Hazardous Substances Data: 330785-83-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester is used as a PDE5 inhibitor for the treatment of erectile dysfunction. Its application is based on its ability to selectively inhibit the PDE5 enzyme, which is responsible for breaking down cyclic guanosine monophosphate (cGMP). By inhibiting PDE5, 5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester enhances the vasodilatory effects of nitric oxide, leading to increased blood flow in the corpus cavernosum of the penis, thus aiding in achieving and maintaining an erection.
Additionally, due to its structural similarity to avanafil, 5-PyriMidinecarboxylic acid,4-[[(3-chloro-4-Methoxyphenyl)Methyl]aMino]-2-[(2S)-2-(hydroxyMethyl)-1-pyrrolidinyl]-, ethyl ester may also have potential applications in other areas where PDE5 inhibition is beneficial, such as in the treatment of pulmonary arterial hypertension or other conditions involving impaired blood flow. Further research and development would be required to explore these potential applications.

Upstream product

• 330785-82-5 4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonyl-2-methylsulfinylpyrimidine 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 53554-29-3 ethyl 4-hydroxy-2-(methylthio)pyrimidine-5-carboxylate 
• 330785-81-4 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-2-(methylsulfanyl)pyrimidine-5-carboxylate 
• 147-85-3 L-proline 
• 372117-76-5 2-methylsulfonyl-5-ethoxycarbonyl-4-(3-chloro-4-methoxybenzylamino)pyrimidine 
• 68832-13-3 D-prolinol 
• 115514-77-7 (3-chloro-4-methoxyphenyl)methanamine 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 41965-95-1 (3-chloro-4-methoxyphenyl)methylamine hydrogen chloride 
• 330785-99-4 2-hydroxy-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine 
• 330786-00-0 2-chloro-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine 
• 28485-17-8 5-carbethoxyuracil 

Downstream Products

• 330784-47-9 avanafil 

Relevant articles and documents

A kind of avanafil impurity D and synthesis method and application thereof

The present invention provides a new aphranarfil impurity and synthesis method thereof, by synthesizing and characterizing the impurity, the structure of the impurity is determined, the drug impurity profile of avanafil is perfected, the resulting product is of high purity, can be used as a control for drug quality control research.

Preparation method of avanafil impurity

The invention discloses a preparation method of an avanafil impurity. The preparation method comprises the following steps: A) taking 4-(3-chloro-4-methoxyphenylamino)-5-ethoxycarbonyl-2-methylthio pyrimidine I as a raw material, and obtaining a compound

Method of preparing medical compound stendra

The invention discloses a method of preparing a medical compound stendra and belongs to the technical field of medical compounds. The key point of the technical scheme is as follows: the synthetic route of the method of preparing the medical compound stendra is as follows: a formula as shown in the description. The method has the advantages of being high in yield, low in cost, economical and environment-friendly, suitable for industrialization, high in product impurity and the like, and is a synthetic method which has industrial production value.

A arab league cuts down that non-intermediate the refined purification method

The invention provides a non-intermediate arab league cuts down that the refined purification method, it mainly utilizes arab league cuts down that non-intermediate 4 - [(3 - chloro - 4 - methoxyphenyl) methylamino] - 2 - [(S)- 2 - hydroxy methyl pyrrole

Method for preparing avanafil raw material medicine

The invention relates to the technical field of medicine synthesis, and discloses a method for preparing an avanafil raw material medicine. The method comprises the following steps: taking a midbody -MI as an initial raw material, and performing an oxidation reaction, a condensation reaction with L-proline, a hydrolysis reaction and a dehydration condensation reaction in sequence, thereby obtaining avanafil. Aiming at the problems that a monitoring and analysis method of a conventional avanafil preparation method is not available, the invention provides a set of effective monitoring and detection method, the quality of middle products and final products can be effectively controlled, meanwhile due to adjusted purification methods of different steps, the purity of the middle products and the final products can be at a relatively high level, and the method is particularly applicable to industrial large-scale production.

Atorvastatin that non-preparation method

The invention relates to a preparation method of avanafil and a new compound provided in a preparation process. According to the method, 5-uracil carboxylic acid or an ester thereof is taken as the raw material, and the avanafil meeting the clinical requirements can be synthesized at a relatively cost; besides, the preparation method is simple and convenient to operate, mild in reaction conditions, high in yield, low in cost, environmentally friendly and suitable for industrial large-scale production of the avanafil.

A 4 - [(3-chloro-4-benzyl) amino] - 2 - [2 - (hydroxymethyl) - 1-pyrrolidinyl] pyrimidine-5-carboxylic acid ethyl ester preparation method

The invention discloses a preparation method of 4-[(3-chlorine-4-methoxyl benzyl) amino]-2-[2-(hydroxymethyl)-1-pyrrolidyl]-pyrimidine-5-nonanoic acid-ethyl ester. The method comprises the following steps: dissolving 4-(3-chlorine-4-methoxyl benzyl amido)-2-methylmercapto pyrimidine-5-nonanoic acid-ethyl ester in an organic solvent; dissolving L-Prolinol in the same organic solvent; respectively controlling flow velocity to put a material liquid into a micro reactor; preheating, mixing, reacting and cooling in the micro reactor to obtain a reactant material liquid, and then discharging the reactant material liquid out of the micro reactor; dripping water into the reactant material liquid for crystallization and then performing suction filtration, washing and drying to obtain the 4-[(3-chlorine-4-methoxyl benzyl) amino]-2-[2-(hydroxymethyl)-1-pyrrolidyl]-pyrimidine-5-nonanoic acid-ethyl ester. By adopting the micro reactor for reaction, instant full mixing of reactant materials of each reaction unit and precise control on reaction temperature can be realized, so that higher reaction yield and selectivity can be obtained, continuity and automation of a reaction process are realized, and the product is high in yield and good in quality.

A arab League cuts down that non-intermediate and its preparation method and application

The invention discloses an avanafil intermediate as well as a preparation method and application thereof. The avanafil intermediate is a compound having a general formula as shown in the description, wherein R in the general formula is selected from C1-C4 alkyl. The preparation method of the intermediate comprises the steps a-d in the synthesis route as shown in the description. The invention also discloses an application of the intermediate. Each reaction step for preparing avanafil from the intermediate has the advantages of simple operation, mild reaction conditions, easily available reaction raw materials, high reaction yield and the like, the products are easy to separate and purify; the total yield of prepared avanafil is increased to 40% and the HPLC purity reaches up to 99.8%; the preparation cost of avanafil is greatly reduced, the quality of avanafil is ensured, and thus the intermediate is very much in line with industrial production requirements and has practical value.

PROCESS FOR THE PREPARATION OF (S)-4-[(3-CHLORO-4-METHOXYBENZYL)AMINO]-2-[2- (HYDROXYMETHYL)-1-PYRROLIDINYL]-N-(2-PYRIMIDINYL METHYL-5-PYRIMIDINE CARBOXAMIDE

The present invention relates to an improved process for the preparation of (S)-4-[(3- chloro-4-methoxybenzyl)amino]-2-[2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinyl ethyl)- 5-pyrimidine carboxamide compound of formula-1 represented by the following structural formula.

BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS

The present invention relates to the technical field of medicine and pharmacy, and particularly relates to bicyclic group substituted pyrimidine compounds represented by general formula (I), pharmaceutical acceptable salts thereof or stereoisomers thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined in the specification. The present invention also relates to preparation methods, pharmaceutical formulations, and pharmaceutical compositions of the compounds, and use of the compounds, pharmaceutical formulations, and pharmaceutical compositions for preparing a medicament for treating and/or preventing sexual dysfuntion diseases and diseases with lower urinay tract symptoms.